Unlocking the Potential of CHRNA9 as a Drug Target and Biomarker

Target Name: CHRNA9

NCBI ID: G55584

CHRNA9

Unlocking the Potential of CHRNA9 as a Drug Target and Biomarker

CHRNA9, also known as nicotinic alpha 9, is a highly expressed gene in the human body that is involved in the regulation of nicotine signaling. It is a G protein-coupled receptor (GPCR), which means it interacts with protein molecules called G proteins. GPCRs are a family of transmembrane proteins that play a crucial role in cellular signaling, including the modulation of ion channels, neurotransmitter release, and cell survival. The activation of CHRNA9 has been shown to have a wide range of physiological effects, including the regulation of neural circuits, muscle contractions, and the modulation of pain perception.

The Potential as a Drug Target

CHRNA9 has been identified as a potential drug target due to its involvement in various physiological processes that can be affected by drugs. One of the key reasons for its potential as a drug target is its involvement in the modulation of pain perception. Pain perception is a complex physiological process that involves the activation of multiple neural circuits in the brain. The neurotransmitter pain signals are released by the activation of different types of neurons, including those involved in pain modulation. The modulation of pain perception by CHRNA9 has been shown to play a crucial role in the regulation of pain sensitivity, and as such, CHRNA9 may be a valuable target for the development of pain-relieving drugs.

Another potential drug target for CHRNA9 is its role in the regulation of neural circuits. CHRNA9 has been shown to play a role in the regulation of neuronal excitability and synaptic plasticity, which are critical for the development and maintenance of neural circuits. The modulation of neuronal excitability by CHRNA9 has been shown to be involved in the regulation of various cognitive functions, including attention, memory, and learning. As such, CHRNA9 may be a valuable target for the development of drugs that can enhance cognitive function or treat neurological disorders.

The Potential as a Biomarker

CHRNA9 has also been identified as a potential biomarker for various physiological processes. The regulation of nicotine signaling by CHRNA9 has been shown to play a role in the modulation of gene expression, including the regulation of pain perception, neurotransmitter release, and cell survival. The activation of CHRNA9 has been shown to increase the expression of genes involved in pain modulation, including the pain-related gene, TrkA. The modulation of gene expression by CHRNA9 has also been shown to play a role in the regulation of neurotransmitter release, including the regulation of dopamine release in response to nicotine.

In addition to its role in the regulation of neurotransmitter release, CHRNA9 has also been shown to play a role in the regulation of cell survival. The modulation of cell survival by CHRNA9 has been shown to play a role in the regulation of cellular processes such as cell migration, cell proliferation, and apoptosis. The regulation of cell survival by CHRNA9 has been shown to play a critical role in the development and progression of various diseases, including cancer.

Conclusion

In conclusion, CHRNA9 is a GPCR that is involved in the regulation of various physiological processes in the human body. Its involvement in the modulation of pain perception, neural circuits, and cell survival makes it a potential drug target and biomarker. The regulation of nicotine signaling by CHRNA9 also makes it a potential target for the development of drugs that can aid in the treatment of nicotine addiction. Further research is needed to fully understand the role of CHRNA9 in the regulation of various physiological processes and its potential as a drug target and biomarker.

Protein Name: Cholinergic Receptor Nicotinic Alpha 9 Subunit

Functions: Ionotropic receptor with a probable role in the modulation of auditory stimuli. Agonist binding induces a conformation change that leads to the opening of an ion-conducting channel across the plasma membrane (PubMed:11752216, PubMed:25282151). The channel is permeable to a range of divalent cations including calcium, the influx of which may activate a potassium current which hyperpolarizes the cell membrane (PubMed:11752216, PubMed:25282151). In the ear, this may lead to a reduction in basilar membrane motion, altering the activity of auditory nerve fibers and reducing the range of dynamic hearing. This may protect against acoustic trauma. May also regulate keratinocyte adhesion (PubMed:11021840)

The "CHRNA9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CHRNA9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets